You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

37 search results for: asthma

On-Treatment <b>Asthma</b> Remission: Moving Beyond Control

interactivity

On-Treatment Asthma Remission: Moving Beyond Control

5 min

Pulmonology

Learn about the proposed framework for clinical remission in patients with asthma

videoanimation

Asthma White Board Video

2 min

Pulmonology

Learn about type 2 inflammation in asthma, and the burden of asthma on patients and their families.

IgE as a Biomarker for Type 2 <b>Asthma</b>

expert video

IgE as a Biomarker for Type 2 Asthma

14 min

Pulmonology

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

Type 2 Inflammation Underpins Pediatric Severe <b>Asthma</b>

Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

Type 2 Inflammation Mediates Severe <b>Asthma</b> in Pediatric Patients

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Clinical Remission as a Goal in <b>Asthma</b> Clinical Practice

expert video

Clinical Remission as a Goal in Asthma Clinical Practice

2 min

Pulmonology

Profs. Alberto Papi and Ian Pavord discuss clinical remission as a goal in asthma clinical practice beyond symptom control

Airway Remodeling in Type 2 <b>Asthma</b> is Driven by IL-4 and IL-13

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

FeNO: A Biomarker of Type 2 Inflammation in Pediatric <b>Asthma</b> Patients

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma

Why Is It Important to Assess Lung Function in Pediatric <b>Asthma</b>

interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

5 min

Pulmonology

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma

Pediatric <b>Asthma</b> Patient Case Tool: Ash

interactivity

Pediatric Asthma Patient Case Tool: Ash

5 min

Pulmonology

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

The Cycle of Inflammation in Adult <b>Asthma</b>

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients

videoanimation

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

4 min

Pulmonology

Explore the impact of type 2 inflammation and airway remodeling on lung function decline in asthma.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region